

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

<p>1. Name and Address of Reporting Person*</p> <p>CURRY ROBERT E</p> <hr/> <p>(Last) (First) (Middle)</p> <p>C/O THE SPROUT GROUP 3000 SAND HILL ROAD BUILDING 1, SUITE 170</p> <hr/> <p>(Street)</p> <p>MENLO PARK CA 94025</p> <hr/> <p>(City) (State) (Zip)</p>	<p>2. Issuer Name and Ticker or Trading Symbol</p> <p>XCYTE THERAPIES INC [XCYT]</p> <hr/> <p>3. Date of Earliest Transaction (Month/Day/Year)</p> <p>03/19/2004</p> <hr/> <p>4. If Amendment, Date of Original Filed (Month/Day/Year)</p>	<p>5. Relationship of Reporting Person(s) to Issuer (Check all applicable)</p> <p><input checked="" type="checkbox"/> Director 10% Owner</p> <p>Officer (give title below) Other (specify below)</p> <hr/> <p>6. Individual or Joint/Group Filing (Check Applicable Line)</p> <p><input checked="" type="checkbox"/> Form filed by One Reporting Person</p> <p>Form filed by More than One Reporting Person</p>
--	--	---

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/19/2004		C		10,670	A	\$0	0	I	See Footnotes ⁽¹⁾⁽²⁾
Common Stock	03/19/2004		C		478,466	A	\$0	0	I	See Footnotes ⁽¹⁾⁽³⁾
Common Stock	03/19/2004		C		99,172	A	\$0	0	I	See Footnotes ⁽¹⁾⁽⁴⁾
Common Stock	03/19/2004		C		207,805	A	\$0	0	I	See Footnotes ⁽¹⁾⁽⁵⁾
Common Stock	03/19/2004		C		58,861	A	\$0	0	I	See Footnotes ⁽¹⁾⁽⁶⁾
Common Stock	03/19/2004		C		64,741	A	\$0	0	I	See Footnotes ⁽¹⁾⁽⁷⁾
Common Stock	03/19/2004		C		660	A	\$0	0	I	See Footnotes ⁽¹⁾⁽⁸⁾
Common Stock	03/19/2004		C		35,360	A	\$0	0	I	See Footnotes ⁽¹⁾⁽⁹⁾
Common Stock	03/19/2004		C		5,229	A	\$0	960,964	I	See Footnotes ⁽¹⁾⁽¹⁰⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Convertible Promissory Note	\$9.625	03/19/2004		C			10,670	(12)	03/19/2004	Common Stock	10,670	\$9.625	0	I	See Footnotes ⁽¹⁾⁽²⁾
Series A Convertible Preferred Stock	(11)	03/19/2004		C			478,466	(12)	03/19/2004	Common Stock	478,466	\$5.225	0	I	See Footnotes ⁽¹⁾⁽³⁾
Series B Convertible Preferred Stock	(11)	03/19/2004		C			99,172	(12)	03/19/2004	Common Stock	99,172	\$6.05	0	I	See Footnotes ⁽¹⁾⁽⁴⁾
Series C Convertible Preferred Stock	(11)	03/19/2004		C			207,805	(12)	03/19/2004	Common Stock	207,805	\$9.185	0	I	See Footnotes ⁽¹⁾⁽⁵⁾
Series D Convertible Preferred Stock	(11)	03/19/2004		C			58,861	(12)	03/19/2004	Common Stock	58,861	\$15.29	0	I	See Footnotes ⁽¹⁾⁽⁶⁾

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series E Convertible Preferred Stock	(11)	03/19/2004		C			64,741	(12)	03/19/2004	Common Stock	64,741	\$15.29	0	I	See Footnotes ⁽¹⁾⁽⁷⁾
Series F Convertible Preferred Stock	(11)	03/19/2004		C			660	(12)	03/19/2004	Common Stock	660	\$15.29	0	I	See Footnotes ⁽¹⁾⁽⁸⁾
Common Stock Warrant (Right to Buy)	\$0.055	03/19/2004		X			35,360	(12)	03/19/2004	Common Stock	35,360	\$0.055	0	I	See Footnotes ⁽¹⁾⁽⁹⁾
Common Stock Warrant (Right to Buy)	\$1.65	03/19/2004		X			5,229	(12)	03/19/2004	Common Stock	5,229	\$1.65	0	I	See Footnotes ⁽¹⁾⁽¹⁰⁾

Explanation of Responses:

1. See Attachment
2. See Attachment
3. See Attachment
4. See Attachment
5. See Attachment
6. See Attachment
7. See Attachment
8. See Attachment
9. See Attachment
10. See Attachment
11. 1-for-1
12. Immediately

/s/ Joanna Lin Black, as
Attorney-in-Fact for Robert E. Curry 03/23/2004

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Reporting Person	Issuer Name and Ticker Symbol	Statement for MM/DD/YY
Robert E. Curry c/o The Sprout Group 3000 Sand Hill Road Building 1, Suite 170 Menlo Park, CA 94025	Xcyte Therapies, Inc. (XCYT)	3/19/04

- (1) Sprout Capital VII, L.P. ("Sprout VII"), Sprout CEO Fund, L.P. ("Sprout CEO"), DLJ First ESC, L.P. ("ESC") and Sprout Plan Investors, L.P. ("Plan Investors") are Delaware limited partnerships. DLJ Capital Corporation ("DLJCC") is also the general partner of Sprout CEO and the managing general partner of Sprout VII and, as such, is responsible for their day-to-day management. DLJCC makes all of the investment decisions on behalf of Sprout VII and Sprout CEO. DLJ Associates VII, L.P. ("Associates VII"), a Delaware limited partnership, is a general partner of Sprout VII and in accordance with the terms of the relevant partnership agreement, does not participate in investment decisions made on behalf of Sprout VII. DLJ Capital Associates VII, Inc. ("DLJCA VII"), a Delaware corporation and wholly-owned subsidiary of CSFB-USA, is the managing general partner of Associates VII. DLJ LBO Plans Management Corporation ("DLJLBO"), a Delaware corporation, is the general partner of ESC and, as such, is responsible for its day-to-day management. DLJLBO makes all of the investment decisions on behalf of ESC. DLJ LBO Plans Management Corporation II ("DLJLBOII"), a Delaware corporation, is the general partner of Plan Investors and, as such, is responsible for its day-to-day management. DLJLBOII makes all of the investment decisions on behalf of Plan Investors. DLJLBO and DLJLBOII are wholly-owned subsidiaries of Credit Suisse First Boston Private Equity, Inc. ("CSFBPE"), a Delaware corporation, which, in turn, is a wholly-owned subsidiary of CSFB-USA.
- (2) Includes 213 shares of Common Stock, upon conversion of convertible promissory notes held of record by DLJ Capital Corporation, 1,067 shares of Common Stock, upon conversion of convertible promissory notes held of record by Sprout Plan Investors, L.P., 9,283 shares of Common Stock, upon conversion of convertible promissory notes held of record by Sprout Capital VII, L.P. and 107 shares of Common Stock, upon conversion of convertible promissory notes held of record by Sprout CEO Fund, L.P., all of which convertible promissory notes were converted to Common Stock upon the closing of the issuer's initial public offering. Dr. Curry disclaims beneficial ownership of shares held by these entities except to the extent of his pecuniary interest therein.
- (3) Includes 9,569 shares of Series A Convertible Preferred Stock held of record by DLJ Capital Corporation., 47,846 shares of Series A Convertible Preferred Stock held of record by DLJ First ESC., L.P., 416,217 shares of Series A Convertible Preferred Stock held of record by Sprout Capital VII, L.P., and 4,834 shares of Series A Preferred Convertible Stock held of record by Sprout CEO Fund, L.P., all of which shares automatically converted to Common Stock upon the closing of the issuer's initial public offering. Dr. Curry disclaims beneficial ownership of shares held by these entities except to the extent of his pecuniary interest therein.
- (4) Includes 1,983 shares of Series B Convertible Preferred Stock held of record by DLJ Capital Corporation., 9,917 shares of Series B Convertible Preferred Stock held of record by DLJ First ESC., L.P., 86,270 shares of Series B Convertible Preferred Stock held of record by Sprout Capital VII, L.P., and 1,002 shares of Series B Preferred Convertible Stock held of record by Sprout CEO Fund, L.P., all of which shares automatically converted to Common Stock upon the closing of the issuer's initial public offering. Dr. Curry disclaims beneficial ownership of shares held by these entities except to the extent of his pecuniary interest therein.
- (5) Includes 4,156 shares of Series C Convertible Preferred Stock held of record by DLJ Capital Corporation., 20,780 shares of Series C Convertible Preferred Stock held of record by DLJ First ESC., L.P., 180,770 shares of Series C Convertible Preferred Stock held of record by Sprout Capital VII, L.P., and 2,099 shares of Series C Preferred Convertible Stock held of record by Sprout CEO Fund, L.P., all of which shares automatically converted to Common Stock upon the closing of the issuer's initial public offering. Dr. Curry disclaims beneficial ownership of shares held by these entities except to the extent of his pecuniary interest therein.
- (6) Includes 1,177 shares of Series D Convertible Preferred Stock held of record by DLJ Capital Corporation., 5,886 shares of Series D Convertible Preferred Stock held of record by DLJ First ESC., L.P., 51,204 shares of Series D Convertible Preferred Stock held of record by Sprout Capital VII,

L.P., and 594 shares of Series D Preferred Convertible Stock held of record by Sprout CEO Fund, L.P., all of which shares automatically converted to Common Stock upon the closing of the issuer's initial public offering. Dr. Curry disclaims beneficial ownership of shares held by these entities except to the extent of his pecuniary interest therein.

- (7) Includes 1,308 shares of Series E Convertible Preferred Stock held of record by DLJ Capital Corporation., 6,540 shares of Series E Convertible Preferred Stock held of record by DLJ First ESC., L.P., and 56,893 shares of Series E Convertible Preferred Stock held of record by Sprout Capital VII, L.P., all of which shares automatically converted to Common Stock upon the closing of the issuer's initial public offering. Dr. Curry disclaims beneficial ownership of shares held by these entities except to the extent of his pecuniary interest therein.
- (8) Includes 660 shares of Series F Convertible Preferred Stock held of record by Sprout CEO Fund, L.P., all of which shares automatically converted to Common Stock upon the closing of the issuer's initial public offering. Dr. Curry disclaims beneficial ownership of shares held by these entities except to the extent of his pecuniary interest therein.
- (9) Includes 707 shares of Common Stock issuable upon exercise of warrants held of record by DLJ Capital Corporation, 3,535 shares of Common Stock issuable upon exercise of warrants held of record by DLJ First ESC, L.P., 30,762 shares of Common Stock issuable upon exercise of warrants held of record by Sprout Capital VII, L.P. and 356 shares of Common Stock issuable upon the exercise of warrants held of record by Sprout CEO Fund, L.P., all of which warrants were exercised upon the closing of the issuer's initial public offering through a net exercise feature at the initial public offering price.
- (10) Includes 103 shares of Common Stock issuable upon exercise of warrants held of record by DLJ Capital Corporation, 523 shares of Common Stock issuable upon exercise of warrants held of record by DLJ First ESC, L.P., 4,551 shares of Common Stock issuable upon exercise of warrants held of record by Sprout Capital VII, L.P. and 52 shares of Common Stock issuable upon the exercise of warrants held of record by Sprout CEO Fund, L.P., all of which warrants were exercised upon the closing of the issuer's initial public offering through a net exercise feature at the initial public offering price.